LESSONS FROM ONTARGET

REFERENCES

• Ezzati M, Hoorn SV, Rodgers A, et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362:271–80.
   PubMed Web of Science ®Google Scholar
• Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004; 291:2616–22.
   PubMed Web of Science ®Google Scholar
• Van de Casseye, F. Notre Coeur, Nos Artères No. 3, mai-juin 2005.
   Google Scholar
• Eurostat Yearbook 2006–07, Chapter 1. Population, p.62.
   Google Scholar
• Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hy-pertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749–56.
   PubMed Web of Science ®Google Scholar
• Lucius R, Gallinat S, Busche S, Rosenstiel P, Unger T. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999; 56:1008–19.
   Web of Science ®Google Scholar
• Oliverio MI, Coffman TM. Angiotensin-I I-receptors: new targets for a ntihypertensive therapy. Clin Cardiol 1997; 20:3–6.
   PubMed Web of Science ®Google Scholar
• Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8:565–72.
   PubMed Web of Science ®Google Scholar
• Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-re-ceptor mediates inhibition of cell proliferation in coronary endothelial Clin Invest 1995; 95: 651–7.
   Google Scholar
• Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23:59–517.
   Google Scholar
• Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pa-thobiology of vascular disease: a unifying hypothesis. Hyperten-sion 2001; 37:1047–52.
   PubMed Web of Science ®Google Scholar
• Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002; 18:1331–9.
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII.The angiotensin II receptors. Pharmacol Rev 2000; 52:415–72.
   PubMed Web of Science ®Google Scholar
• Kimura B, Sumners C, Phillips MI. Changes in skin angiotensin II receptors in rats during wound healing. Biochem Biophys Res Commun 1992; 187:1083–90.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92:10663–7.
   PubMed Web of Science ®Google Scholar
• Unger T, Chung O, Csikos T, et al. Angiotensin receptors. J Hy-pertens Suppl 1996; 14:S95–S103.
   PubMed Web of Science ®Google Scholar
• Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evi-dence. J Hypertens Suppl 1998; 16:53–59.
   Google Scholar
• Unger T. The role of the renin-angiotensin system in the deve-lopment of cardiovascular disease. Am J Cardiol 2002; 89:3A–9A.
   Google Scholar
• Unger T, Stoppelhaar M. Rationale for double renin-angiotensin-a ldosterone system blockade. Am J Cardiol 2007; 100:25J–31J.
   Google Scholar
• Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 1999; 12:5189–594.
   Google Scholar
• Chen R, Iwai M, Wu L, et al. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003; 42:542–7.
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Thera-peutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000; 2:258–62.
   PubMedGoogle Scholar
• Hanon S, Vijayaraman P, Sonnenblick EH, Le JemtelTH. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibi-tors in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2000; 1:147–50.
   PubMedGoogle Scholar
• Doggrell SA. Angiotensin AT-1 receptor antagonism: comple-mentary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin Pharmacother 2002; 3:1543–56.
   PubMedGoogle Scholar
• Steckelings UM, Kaschina E, Unger T. The AT2 receptor--a matter of love and hate. Peptides 2005; 26:1401–9.
   PubMed Web of Science ®Google Scholar
• Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109:8–13.
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.The SOLVD I nvestigattors. NEnglJ Med 1992; 327:685–91.
   Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dys-function after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Eng(' Med 1992; 327:669–77.
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, mu lticentre trial (the EUROPA study). Lancet 2003; 362:782–8.
   PubMed Web of Science ®Google Scholar
• Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358:2130–1.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con-verting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl I Med 2000; 342:145–53.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang J. Do ancillary properties of antihypertensive drugs explain the outcome results of recent trials? J Nephrol 2002; 15:422–7.
   Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28:385–407.
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-con-verting-enzyme inhibition in stable coronary artery disease. N EnglJ Med 2004; 351:2058–68.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022–31.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candes-artan in patients with chronic heart failure and reduced left-ventricular systolic function taking a ngiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767–71.
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor Mocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117–24.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, Left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893–906.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart fai-lure: the CHARM-Overall programme. Lancet 2003; 362:759–66.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evalu-ation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560–72.
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardi-ology/American Heart Association Task Force on Practice Gui-delines (Committee to revise the 1995 Guidelines for the Eva-luation and Management of Heart Failure). I Am Coll Cardiol 2001; 38:2101–13.
   PubMed Web of Science ®Google Scholar
• Mancia G, De BG, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardio-logy (ESC)../Hypertens 2007; 25:1105–87.
   Google Scholar
• National Kidney Foundation. Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12–S154.
   Google Scholar
• Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363–72.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diag-nosis and treatment of chronic heart failure: executive sum-mary (update 2005): The Task Force for the Diagnosis and Tre-atment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115–40.
   PubMed Web of Science ®Google Scholar
• Sleight P. The ONTARGET/TRANSCEND Trial Programme: base-line data. Acta Diabetol 2005; 42 Suppl 1:S50–S6.
   Google Scholar
• Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148:52–61.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547–59.
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Tirschwell DL, LongstrethWT, Jr., et al. Vascula r events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005; 65:835–42.
   PubMed Web of Science ®Google Scholar
• Costa FV. Telmisartan - Standing Out in a Crowded Contest ? High Blood Press Cardiovasc Prey 2006; 13:85–94.
   Google Scholar
• Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor Mockers for treating es-sential hypertension. Ann Intern Med 2008; 148:16–29.
   PubMed Web of Science ®Google Scholar